Try our beta test site
12 studies found for:    ly2606368
Show Display Options
Rank Status Study
1 Recruiting A Study of Prexasertib (LY2606368) in Japanese Participants With Advanced Cancers
Condition: Neoplasm
Intervention: Drug: Prexasertib
Phase: Phase 1
Sponsor: Eli Lilly and Company
First Received: July 31, 2015
2 Recruiting LY2606368 in Combination With Cytarabine and Fludarabine in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HRMDS)
Condition: Leukemia
Interventions: Drug: Fludarabine;   Drug: Cytarabine;   Drug: LY2606368
Phase: Phase 1
Sponsor/Collaborators: M.D. Anderson Cancer Center;   Eli Lilly and Company
First Received: January 5, 2016
3 Recruiting A Study of LY2606368 in Participants With Advanced Cancer
Condition: Advanced Cancer
Interventions: Drug: [¹⁴C]LY2606368;   Drug: LY2606368
Phase: Phase 1
Sponsor: Eli Lilly and Company
First Received: May 18, 2016
4 Recruiting A Study of Prexasertib (LY2606368) in Participants With Extensive Stage Disease Small Cell Lung Cancer
Condition: Small Cell Lung Cancer
Intervention: Drug: Prexasertib
Phase: Phase 2
Sponsor: Eli Lilly and Company
First Received: March 31, 2016
5 Not yet recruiting Prexasertib in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors
Conditions: Childhood Solid Neoplasm;   Recurrent Central Nervous System Neoplasm;   Refractory Central Nervous System Neoplasm
Interventions: Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Drug: Prexasertib
Phase: Phase 1
Sponsor/Collaborators: Children's Oncology Group;   National Cancer Institute (NCI);   COG Phase 1 Consortium
First Received: June 15, 2016
6 Recruiting A Study of Prexasertib (LY2606368) in Combination With Ralimetinib in Participants With Advanced or Metastatic Cancer
Conditions: Advanced Cancer;   Metastatic Cancer;   Colorectal Cancer;   Non-small Cell Lung Cancer
Interventions: Drug: prexasertib;   Drug: ralimetinib
Phase: Phase 1
Sponsor: Eli Lilly and Company
First Received: August 5, 2016
7 Recruiting A Study of Prexasertib (LY2606368) With Chemotherapy and Radiation in Participants With Head and Neck Cancer
Condition: Head and Neck Neoplasms
Interventions: Drug: Prexasertib;   Drug: Cisplatin;   Drug: Cetuximab;   Radiation: Intensity Modulated Radiation Therapy
Phase: Phase 1
Sponsor: Eli Lilly and Company
First Received: September 18, 2015
8 Not yet recruiting Combination Study of Prexasertib and Olaparib in Patients With Advanced Solid Tumors
Condition: Solid Tumor
Interventions: Drug: Prexasertib;   Drug: Olaparib
Phase: Phase 1
Sponsor/Collaborators: Khanh Do;   Eli Lilly and Company;   AstraZeneca;   Dana-Farber Cancer Institute
First Received: February 10, 2017
9 Recruiting A Study of LY2606368 (Prexasertib) in Patients With Solid Tumors With Replicative Stress or Homologous Repair Deficiency
Condition: Advanced Cancers
Intervention: Drug: LY2606368
Phase: Phase 2
Sponsor: Dana-Farber Cancer Institute
First Received: August 17, 2016
10 Recruiting A Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) in BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, High Grade Serous Ovarian Cancer, and Metastatic Castrate-Resistant Prostate Cancer
Conditions: Ovarian Cancer;   Breast Cancer;   Prostate Cancer
Intervention: Drug: LY2606368
Phase: Phase 2
Sponsor/Collaborators: National Cancer Institute (NCI);   National Institutes of Health Clinical Center (CC)
First Received: July 29, 2014
11 Completed A Phase 1 Study in Participants With Advanced Cancer
Conditions: Advanced Cancer;   Squamous Cell Carcinoma;   Carcinoma, Squamous Cell of Head and Neck;   Lung Squamous Cell Carcinoma Stage IV;   Anal Squamous Cell Carcinoma;   Carcinoma, Non-Small-Cell Lung
Intervention: Drug: Prexasertib
Phase: Phase 1
Sponsor: Eli Lilly and Company
First Received: April 28, 2010
12 Recruiting A Study of Prexasertib (LY2606368) With Chemotherapy or Targeted Agents in Participants With Advanced Cancer
Conditions: Neoplasm Metastasis;   Colorectal Neoplasms
Interventions: Drug: Prexasertib;   Drug: Cisplatin;   Drug: Cetuximab;   Drug: G-CSF;   Drug: Pemetrexed;   Drug: Fluorouracil;   Drug: LY3023414;   Drug: Leucovorin
Phase: Phase 1
Sponsor: Eli Lilly and Company
First Received: April 24, 2014

Study has passed its completion date and status has not been verified in more than two years.